Table 6 Multivariate Cox regression analysis of the impact of lncRNA signature and clinicopathological features on OS and DFS in the three NSCLC patient cohorts

3.18 (1.62–6.23)

0.001

2.17 (1.35–3.47)

0.001

1.07 (0.78–1.45)

0.401

1.03 (0.76–1.40)

0.845

1.61 (0.57–4.51)

0.365

1.42 (0.54–3.73)

0.474

1.61 (1.09–2.15)

0.008

1.47 (1.06–2.05)

0.022

0.99 (0.61–1.61)

0.965

0.94 (0.58–1.51)

0.783

0.91 (0.47–1.73)

0.767

0.86 (0.45–1.64)

0.657

1.18 (0.78–1.78)

0.43

1.12 (0.75–1.68)

0.587

1.60 (0.85–3.01)

0.147

1.79 (0.96–3.35)

0.068

2.17 (0.75–6.28)

0.154

1.86 (0.65–5.34)

0.248

2.94 (1.15–7.50)

0.024

2.60 (1.09–6.24)

0.032

0.58 (0.25–1.37)

0.218

0.53 (0.23–1.25)

0.146

2.41 (1.47–3.97)

0.001

2.49 (1.53–4.05)

<0.001

1.14 (0.87–1.49)

0.359

1.13 (0.87–1.48)

0.349

0.64 (0.32–1.27)

0.201

0.79 (0.41–1.55)

0.498

1.40 (1.03–1.91)

0.031

1.40 (1.04–1.88)

0.026

0.92 (0.62–1.38)

0.697

0.94 (0.63–1.4)

0.763

1.41 (0.80–2.49)

0.240

1.27 (0.73–2.23)

0.402

0.89 (0.59–1.32)

0.552

0.88 (0.60–1.31)

0.537

1.42 (0.85–2.39)

0.185

1.51 (0.90–2.52)

0.116

5.40 (1.73–16.8)

0.004

4.91 (1.59–15.17)

0.006

0.54 (0.28–1.04)

0.064

0.52 (0.27–1.00)

0.050

1.22 (0.66–2.28)

0.521

1.48 (0.81–2.70)

0.206

1.88 (1.15–3.08)

0.012

1.80 (1.14–2.84)

0.012

1.00 (0.70–1.42)

0.988

1.19 (0.86–1.66)

0.294

0.80 (0.46–1.40)

0.430

0.70 (0.42–1.18)

0.183

1.80 (1.28–2.54)

0.001

1.69 (1.24–2.30)

0.001

1.26 (0.74–2.13)

0.395

1.12 (0.69–1.84)

0.640

1.78 (1.06–2.97)

0.028

1.92 (1.19–3.09)

0.008

1.66 (1.03–2.66)

0.037

1.81 (1.16–2.83)

0.009

1.26 (0.68–2.33)

0.466

1.59 (0.87–2.91)

0.130

1.75 (0.39–7.92)

0.468

2.81 (0.79–9.98)

0.110